Medtronic plc

Medtronic's growth has accelerated, but by about half what the headline shows. First-quarter fiscal 2027 organic revenue growth of 13.7% includes a 14th week that the company values at about $570M. Without it, underlying growth is roughly 7% by my calculation. Electrophysiology carries much of that gain, while Medical Surgical turned 10% more sales into no more profit ($485M vs $486M). Cash generation comfortably covers the dividend, but money is moving into deals funded partly with short-term debt. Large legal exposures sit alongside this with no liability recorded, led by a $382M antitrust verdict that the court will triple.

• Revenue was $9,756M against $8,578M a year earlier, up 13.7% both reported and organic. The quarter had 14 weeks against 13.
• Diluted EPS was $1.14 vs $0.81 under GAAP and $1.45 vs $1.26 non-GAAP. Non-GAAP operating margin was 23.7%, up 10 basis points.
• FY27 guidance was raised:
• organic growth to 7.25%–7.75% (previously 6.75%–7.25%);
• non-GAAP EPS to $5.94–$6.00 (previously $5.90–$6.00).
• Deals:
• Scientia Vascular closed June 12 at a $681M total purchase price, including $123M contingent.
• SPR Therapeutics closed July 16 at $654M.
• A $700M Cornerstone Robotics investment was paid in Q2.
• On August 4, 2026 a federal jury awarded $88M in the first hernia-mesh trial. Medtronic recorded no liability.

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

• Underlying growth is about 7%, and the guidance raise only banks the first-quarter beat
• Electrophysiology carries the acceleration; several franchises are weak even with the extra week
• Medical Surgical grew sales 10% but not profit, and its cushions are thin
• Cash is shifting from buybacks to deals whose returns are not yet visible

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what MDT files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on MDT say?” Add Viridis to Claude, or to ChatGPT.